146 related articles for article (PubMed ID: 9168177)
1. Urokinase-type plasminogen activator and its receptor in bladder cancer.
Hasui Y; Osada Y
J Natl Cancer Inst; 1997 May; 89(10):678-9. PubMed ID: 9168177
[No Abstract] [Full Text] [Related]
2. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
3. Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Duffy MJ; Duggan C
J Natl Cancer Inst; 1997 Nov; 89(21):1628-30. PubMed ID: 9362165
[No Abstract] [Full Text] [Related]
4. Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hasui Y; Osada Y
J Natl Cancer Inst; 1997 Nov; 89(21):1630-1. PubMed ID: 9362166
[No Abstract] [Full Text] [Related]
5. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
7. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
8. Re: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
See WA
J Natl Cancer Inst; 1998 Sep; 90(17):1303. PubMed ID: 9731738
[No Abstract] [Full Text] [Related]
9. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
10. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
13. Serine proteases and brain damage - contribution of the urokinase- plasminogen activator system.
Schwab JM; Meyermann R; Schluesener HJ
Trends Neurosci; 2001 Jan; 24(1):8-9. PubMed ID: 11261939
[No Abstract] [Full Text] [Related]
14. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system.
Vassalli JD; Wohlwend A; Belin D
Curr Top Microbiol Immunol; 1992; 181():65-86. PubMed ID: 1330446
[No Abstract] [Full Text] [Related]
15. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
16. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
17. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
18. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
19. The plasminogen activator system: biology and regulation.
Irigoyen JP; Muñoz-Cánoves P; Montero L; Koziczak M; Nagamine Y
Cell Mol Life Sci; 1999 Oct; 56(1-2):104-32. PubMed ID: 11213252
[TBL] [Abstract][Full Text] [Related]
20. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
